11 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Telezon has dispatched the first of three shiments for the 500,000 SoloFlow commercial order to Serum Institute of India (SII). These needles (along with remaining shipments) will be used in SII's vaccine kits for the world market. The two remaining shipments will be delivered in the next few months, fulfilling SII's first order with Telezon.
Following the involvement with the Victorian Life Sciences Trade Mission in February 2013, Telezon is in discussions with several global organisations about potential supply of our products.
Telezon's SoloFlow needles are being used in SII's vaccination kits for the developing markets. Following a shipment of 28,600 needles, SII approved Telezon/SSB as an official vendor of the SoloFlow needle and ordered a further half a million units for their vaccination kits. This shipment is the first of three which will be delivered over the next few months. The board of Telezon has expressed its pleasure that the company is consistently achieving its commercial outcomes in global markets, and in turn, continuously creating value and awareness for its unique suite of medical device solutions.
The company is currently pursuing capital investment to accelerate commercialization of our other world-patented products and technologies such as the Blunt SoloFlow; DuoDraw; and PolyDermic solutions. The company's solid record of accomplishments and expanding markets demonstrates a rapidly growing demand for our products and further supports this pursuit of investment.